Chimeric antigen receptor (CAR)-T cell therapies have become an important treatment modality for cancer but there remains significant opportunity to enhance CAR-T therapies and leverage these therapeutics to address unmet clinical needs. As these therapies evolve, their application is expanding beyond hematologic malignancies and advancements in science and technology are improving their efficacy, safety, and durability of response. Next-generation CAR-T therapies have the potential to further transform the cancer treatment landscape by positively impacting outcomes, reducing toxicities and logistical complexity, and enhancing patient accessibility and convenience.
In this webinar, we explore the latest innovations in CAR-T therapy and discuss key operational considerations aimed at improving the efficiency of clinical trials and enriching the experience of study participation for oncology patients.
Topics include:
- Recent advancements in CAR-T therapy design and application
- Impact of next-generation CAR-T therapies on clinical trial operations
- Strategies for reducing the burden of CAR-T study participation
Speakers:
Ashley Herrick, Ph.D., VP, Oncology Strategy
Meera Belur, Executive Director, Program Strategy, Oncology
